[{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"ProBioGen","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Partnership","leadProduct":"MAR002","moa":"GHS receptor","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Marea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marea Therapeutics \/ ProBioGen","highestDevelopmentStatusID":"5","companyTruncated":"Marea Therapeutics \/ ProBioGen"}]

Find Endocrinology Clinical Drug Pipeline Developments & Deals by Marea Therapeutics

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          APGA Annual Conference
                          Not Confirmed
                          APGA Annual Conference
                          Not Confirmed

                          Details : The parternship aims to deliver clinical material for MAR002, Marea’s investigational anti-growth hormone receptor (GHR) antibody for the treatment of acromegaly.

                          Product Name : MAR002

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          March 05, 2025

                          Lead Product(s) : MAR002

                          Therapeutic Area : Endocrinology

                          Highest Development Status : IND Enabling

                          Sponsor : ProBioGen

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank